>Go!
NEWS SEARCH

02.09.2018 | Investors

Allergan Declares First Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share and Provides Annual General Meeting of Shareholders Updates

- Dividend to be Paid on March 28, 2018 -
- Annual General Meeting of Shareholders to be Held May 2, 2018; Record Date of March 6, 2018 -
DUBLIN , Feb. 9, 2018 /PRNewswire/ --  Allergan plc (NYSE: AGN) today announced its Board of Directors has declared a cash dividend of $0.72 per ordinary share for the first quarter of 2018. The dividend will be paid on March 28, 2018 to shareholders of record at the close of business on February 28, 2018 .
Allergan plc logo
Allergan also announced that its 2018 Annual General Meeting of Shareholders will be held on May 2, 2018 in Dublin, Ireland . The Company's Board of Directors has set the close of business on March 6, 2018 as the record date for determining shareholders eligible to vote at the meeting.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland , is a bold, global pharmaceutical company and a leader in a new industry model - Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.
Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission , including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended September 30, 2017 . Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
CONTACTS:  Allergan:
  Investors:
  Daphne Karydas
  (862) 261-8006
   
  Karina Calzadilla
  (862) 261-7328
   
  Media:
  Lisa Brown
  (862) 261-7320
 
CisionView original content with multimedia:http://www.prnewswire.com/news-releases/allergan-declares-first-quarter-2018-cash-dividend-of-072-per-ordinary-share-and-provides-annual-general-meeting-of-shareholders-updates-300596274.html
Media Contacts
Mark Marmur
Global Corporate Media Relations
+1 (862) 261 7558
Fran DeSena
U.S. Product Media Relations
+1 (201) 427-8762
Janet Kettels
International Product Media Relations
+44 773 850 6476

For local media contacts in other countries, please visit the relevant country website.

Investor relations:

Karina Calzadilla
Investor Relations
+1 (862) 261 7488